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1. Introduction 
Several of the cell types present in the rat anterior 
pituitary increase their rates of hormone secretion in 
conditions likely to be associated with raised intra- 
cellular concentrations of adenosine 3':5'-cyclic mono- 
phosphate (cyclic AMP) [1--4]. Furthermore, Steiner 
and co-authors [5] have shown directly that pituitary 
levels of cyclic AMP are elevated under conditions of 
accelerated growth hormone and thyrotropin release; 
intracellular levels of cyclic AMP therefore appear to 
be the principal factor in the regulation of secretion i  
these cells. Since the effects of cyclic AMP in a variety 
of tissues appear to be related to the binding of this 
nucleotide to a specific receptor protein which may 
lead directly to the activation of a protein phospho- 
kinase [6-8] ,  we have investigatecl the occurrence of 
a comparable cyclic AMP-binding protein in extracts 
of rat anterior pituitary and its relationship to protein 
kinase activity extracted from the same tissue. 
In this study a protein has been demonstrated in a 
100,000 g supernatant prepared from rat anterior 
pituitary which, after purification by polyacrylamide 
gel electrophoresis, appeared as a single component 
possessing both cyclic AMP-binding and protein kinase 
activity. The cyclic AMP-stimulated kinase was capable 
of phosphorylating ot only exogenous histone but 
also endogenous pituitary proteins, suggesting a possible 
role of the receptor/kinase complex in the stimulation 
of hormone secretion by cyclic AMP. 
2. Methods 
2.1. Extraction procedures 
Anterior pituitary tissue obtained from male 
Sprague-Dawley rats weighing 300-400 g was utilized 
throughout. In most experiments fragments of tissue 
were homogenised at4 ° in 10 mM sodium phosphate 
buffer (pH 6.5) containing 0.3 M sucrose, particulate 
material was removed by centrifugation f the homo- 
genate at 100,000 g for 40 min in a Spinco Model L2 
centrifuge, the supernatant being decanted and treated 
immediately with 325 mg ammonium sulphate per ml 
solution. The resultant precipitate was centrifuged for 
15 min under the same conditions as before, the super- 
natant being discarded. The precipitate was redissolved 
in buffer containing 10 mM Tris (pH 7.4) and 6 mM 
mercaptoethanol and dialysed against he same buffer. 
The extract remaining after dialysis was stored at -20 ° 
until required. 
Further purification of the crude extract was 
achieved by polyacrylamide g l electrophoresis in the 
system of Davis [9], without he use of sample or 
spacer gels. A final acrylamide concentration f 7% 
was utilized, electrophoresis at 4 mA per tube being 
employed to provide a standard 4 cm migration of a 
bromophenol b ue tracker dye. Cyclic AMP binding 
or protein phosphokinase activities were determined 
directly in 2 mm segments of the gel. 
2.2. Assay for cyclic AMP binding protein 
The binding of cyclic AMP to tissue proteins was 
determined inhomogenates, soluble extracts or 
column eluates by the method of Walton and Garren 
[10]. Distribution of cyclic AMP-binding activity in 
polyacrylamide g ls was determined by soaking the 
gels for 4 hr at 4 ° in 50 mM Tris buffer (pH 7A) con- 
taining 8 mM theophylline and 1 X 10 -7 M 3H-labeUed 
cyclic AMP (specific activity 6.5 Ci/mM; Radiochemi- 
cal Centre, Amersham, England); free cyclic AMP was 
eluted from the gels by washing in water at 4 ° for 16 
hr. The gels were then sliced into 2 mm segments be- 
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fore dissolving in hydrogen peroxide at 60’ overnight; 
radioactivity in each segment was determined in a 
liquid scintillation spectrometer after addition of 
Triton:toluene:PPO scintillant (700:300:5; v/v/w). A 
similar method of assessing the distribution of cyclic 
AMP-binding protein in polyacrylamide gels has 
recently been described by Gill and Garren [ 1 I] . 
2.3. Protein phosphokinase assay 
Protein phosphokinase activity was measured at 
pH 6.5 in 0.2 ml of an assay mixture containing the 
following: 50 mM sodium-DL-fl-glycerophosphate, 20 
mM potassium fluoride, 0.3 mM ethylene glycol-bis- 
@aminoethylether)N,N’-tetra-acetic acid, 5 mM 
theophylline, 3 mg/ml histone (Type HA Sigma), 0.2 
mM y-32P-adenosine triphosphate (ATP) (l-3 X lo6 
cpm), 10 mM magnesium acetate, and tissue extract 
with or without 1 &l cyclic AMP. The reaction was 
started by the addition of enzyme and after 60 min 
incubation at 37’ it was stopped by the addition of 
4 ml of 10% w/v trichloroacetic acid (TCA). Carrier 
protein (0.1 ml of a 5 mglml solution of bovine serum 
albumin) was added to each tube and the precipitated 
proteins were collected by centrifugation, washed 
once with 4 ml of TCA, and redissolved in 0.2 ml 2 N 
sodium hydroxide. The proteins were reprecipitated 
with TCA and washed once more with TCA. The final 
precipitate was counted in a Beckman liquid scintilla- 
tion spectrometer, without the addition of scintillator, 
by the use of Cherenkov radiation. In order to deter- 
mine the distribution of enzyme activity in the poly- 
acrylamide gels, 2 mm segments of the gel were added 
directly to the assay mixture: a similar method of 
assay of protein phosphokinase activity has recently 
been described [ 1 l] . 
Protein concentrations in tissue extracts were 
estimated by the method of Lowry et al. [ 121 utilizing 
crystalline albumin standards. 
3. Results 
Estimations of levels of cyclic AMP-binding protein 
and of cyclic AMP-dependant protein phosphokinase 
in homogenates and extracts showed that over 80% of 
both activities were present in the 100,000 g super- 
natant from tissue homogenates. Centrifugation alone 
achieved a two-fold purification in binding and protein 
294 
kinase activity per unit protein. Ammonium sulphate 
precipitation provided a further enrichment of both 
activities to four times the levels found in the original 
homogenates. Considerable further purification was 
achieved after polyacrylamide gel electrophoresis, the 
binding and cyclic AMP-stimualted protein kinase 
activities possessing identical mobilities in the gel 
system employed (fig. 1). 
Material purified by polyacrylamide gel electro- 
phoresis was used in analyses of the characteristics of 
the binding protein and protein kinase, utilizing 
histone as substrate for the protein kinase. It was 
found that the cyclic AMP-binding protein possessed 
an apparent binding affinity constant for cyclic AMP 
of 1 X 10-s M while the cyclic AMP-dependent pro- 
tein kinase had an activation constant for cyclic AMP 
of 1 X lo-* M and a pH optimum at 6.0. 
It seemed of some interest to determine whether 
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Fig. 1. Distribution of cyclic AMP binding (upper panel) and 
protein kinase activities of pituitary extracts after purification 
by polyacrylamide gel electrophoresis. Protein kinase activity 
was determined in the absence (0) or presence (0) of 1 I.rM 
cyclic AMP. 
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Table 1 
Incorporation of T-~~P-ATP into endogenous pituitary soluble 
proteins in the presence of enzyme purified by polyacrylamide 
gel electrophoresis. 
Additions to 
assay mixture 
cpm 32P incorporated/hr 
-cyclic AMP +cyclic AMP 
None 124 f 61 (6) 309 i 52 (6)* 
CaCl2 (1 X lo4 M) 143 * 30 (12) 225 f 21(12)* 
Colchicine (5 X lo4 M) 113 f 46 (6) 256 f 42 (6)* 
* Indicates values significantly different @ < 0.05) from con- 
trols incubated in absence of cyclic AMP, although not sig- 
nificantly different from each other at the p < 0.05 level. 
the protein kinase present in anterior pituitary homo- 
genates was capable of phosphorylating endogenous 
substrates as well as the histone used in the experi- 
ments already described. For this purpose, pituitary 
fragments were incubated for 90 min at 37” to permit 
decay of endogenous cyclic AMP, after which they 
were homogenized and centrifuged as before for 45 
min, aliquots of the supernatant being utilized in place 
of histone in the protein kinase assay already described. 
The results obtained in these experiments are shown 
in table 1. It is clear that there was some phosphoryla- 
tion of endogenous protein even in the absence of 
added cyclic AMP, the level being significantly in- 
creased in the presence of the nucleotide. Addition of 
calcium (1 mM) or of colchicine (5 X 1 0e4 M) was 
without significant effect on either the basal or cyclic 
AMP-stimulated protein phosphokinase activity under 
these conditions (table 1). 
4. Discussion 
The results reported here provide clear evidence 
for the presence in the rat anterior pituitary of a 
soluble cyclic AMP-binding protein associated with a 
cyclic AMP-dependent protein kinase. Comparable 
associations between these two activities have been 
reported in a number of other mammalian tissues, and 
the characteristics of the binding protein/protein 
phosphokinase complex of the anterior pituitary appear 
to be like those of similar complexes derived from 
brain [6] , adrenal cortex [7] or skeletal muscle [8]. 
We have not so far been able to achieve dissociation 
of binding protein from phosphokinase activities by 
polyacrylamide gel electrophoresis following incuba- 
tion of the complex with low6 M cyclic AMP, in con- 
trast to the findings of Gill and Garren [l l] , This dif- 
ference might be a consequence of phosphodiesterase 
activity remaining in our tissue extracts since prelim- 
ary results suggest hat such a separation may be 
achieved by gel filtration of the complex on Sephadex 
G-200 columns eluted in the presence of cyclic AMP 
[131. 
The demonstration of a cyclic AMP-binding protein/ 
phosphokinase complex in the anterior pituitary is of 
interest in view of the known role of cyclic AMP in 
the regulation of hormone secretion from this gland. 
Furthermore, the observation that the phosphokinase 
can utilize endogenous soluble pituitary protein as 
substrate suggests that one result of an increase in 
intracellular levels of cyclic AMP in viuo may be 
activation of the protein kinase; indeed, such an acti- 
vation has been proposed to account for many of the 
known effects of cyclic AMP in metabolism [8] . 
Calcium, which is essential for cyclic AMP-stimul- 
ated hormone secretion by the pituitary, but which is 
without effect on pituitary adenyl cyclase [5], was 
ineffective in altering the in vitro phosphorylation of 
endogenous substrates. Similarly, colchicine, which 
induces disaggregation of the microtubular protein 
and which has been shown to play a role in the secre- 
tory process in the pancreatic P-cell [ 141 and in the 
thyroid [ 151, was without effect on the rate of phos- 
phorylation of endogenous substrate; this finding is 
consistent with the reported lack of effect of colchicine 
on growth hormone secretion in vitro [ 161. 
The secretion of hormones by the cells of the 
anterior pituitary involves the migration of hormone 
storage granules to the plasma membrane with sub- 
sequent fusion of the granule and plasma membranes 
and liberation of the granule contents into the extra- 
cellular space. The relationship between the elevation 
of intracellular cyclic AMP levels and these secretory 
processes is unknown; it will therefore be of some 
interest to investigate the nature of the endogenous 
substrates of the cyclic AMP-dependant phosphokinase 
and their possible roles as activators or even effecters 
of the secretory mechanism. 
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